eISSN (Online): 2598-0580



Bioscientia Medicina: Journal of Biomedicine & Translational Research

Journal Homepage: www.bioscmed.com

# Efficacy and Safety of Bullectomy versus Conservative Management in Patients with Symptomatic Vanishing Lung Syndrome: A Systematic Review and Meta-Analysis of Respiratory Outcomes

**Raisya Farah Monica[1]*, Oea Khairsyaf[2], Dessy Mizarti[1]**

[1]Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Andalas, Padang, Indonesia

[2]Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Dr. M. Djamil General Hospital, Padang, Indonesia

**ARTICLE INFO**

**Keywords:**
Bullectomy
Conservative management
Giant bullous emphysema
Meta-analysis
Vanishing lung syndrome

***Corresponding author:**
Raisya Farah Monica

**E-mail address:**
raisyafmonica@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/bsm.v9i9.1376

**A B S T R A C T**

**Background:** Vanishing lung syndrome (VLS), a severe form of giant bullous emphysema, causes debilitating dyspnea by compressing functional lung. A critical evidence gap exists regarding the optimal management strategy, forcing a contentious choice between surgical bullectomy and conservative care. This study provides the first meta-analytic synthesis comparing these two approaches. **Methods:** Following PRISMA guidelines, we systematically searched PubMed, Embase, Scopus, and Web of Science for comparative studies (2015-2024) evaluating bullectomy versus conservative management in symptomatic VLS. Primary outcomes were changes in Forced Expiratory Volume in one second (FEV1), St. George's Respiratory Questionnaire (SGRQ) scores, and major complications. Data were pooled using a random-effects model, and bias was assessed with the ROBINS-I tool. **Results:** Six non-randomized studies involving 488 patients were included. The overall risk of bias was moderate to serious. Compared to conservative care, bullectomy was associated with a substantial improvement in FEV1 (Mean Difference: 0.48 L; 95% CI: 0.35 to 0.61) and a profound improvement in quality of life (SGRQ MD: -15.55; 95% CI: -20.21 to -10.89). However, this efficacy was counterbalanced by a nearly six-fold increase in the risk of major complications (Risk Ratio: 5.82; 95% CI: 2.98 to 11.37). **Conclusion:** Our synthesis suggests that for carefully selected patients, bullectomy offers superior physiological and quality-of-life outcomes over conservative management, but at the cost of significantly higher perioperative risk. These findings, derived from low-quality evidence, underscore the critical need for a highly individualized, multidisciplinary approach to patient selection and a thorough shared decision-making process.

## 1. Introduction

Vanishing lung syndrome (VLS) is a clinical and radiological entity that represents one of the most severe and dramatic manifestations of giant bullous emphysema.[1] The term, first coined to describe the striking radiographic appearance of a progressively disappearing lung, refers to a debilitating condition characterized by the development of enormous, air-filled bullae that overwhelm and efface the normal lung parenchyma. These bullae, defined as air-filled spaces greater than 1 cm in diameter with a discernible wall less than 1 mm thick, can expand relentlessly to occupy a vast portion of the thoracic cavity. The diagnosis of VLS is generally established when one or more of these giant bullae occupy at least one-third of a hemithorax, causing a cascade of deleterious physiological consequences through the compression of adjacent, more functional lung tissue and, in advanced cases, a contralateral shift of the mediastinum.[2]

The underlying pathophysiology of VLS is a story of profound architectural destruction at the molecular and cellular levels. The process is rooted in the destructive inflammatory cascade of emphysema, most commonly initiated by the chronic inhalation of toxic particles and gases from cigarette smoke. This noxious stimulus recruits a massive influx of inflammatory cells, particularly neutrophils and macrophages, into the delicate alveolar structures.[3] These activated immune cells release a potent cocktail of proteases, chief among them being neutrophil elastase and various matrix metalloproteinases (MMPs), such as MMP-9 and MMP-12. In a healthy lung, the activity of these enzymes is tightly regulated by a sophisticated system of endogenous anti-proteases, most notably alpha-1 antitrypsin (AAT) and tissue inhibitors of metalloproteinases (TIMPs). In emphysema, this critical protease-antiprotease balance is overwhelmed. The constant inflammatory onslaught, combined with the oxidative inactivation of anti-proteases by cigarette smoke, leads to uncontrolled enzymatic degradation of the lung's extracellular matrix. The structural backbone of the lung—composed of elastin and collagen fibers that provide its tensile strength and elastic recoil—is progressively dismantled. This relentless destruction of alveolar walls causes smaller airspaces to coalesce, forming the characteristic giant, non-functional bullae. These bullae represent physiological dead space; they are often ventilated but lack a functional capillary bed, rendering them incapable of participating in gas exchange and creating a severe ventilation-perfusion (V/Q) mismatch that contributes to hypoxemia.

The pathophysiology extends beyond this impairment of gas exchange into a profound derangement of respiratory mechanics. The loss of elastic recoil means the lung can no longer passively deflate during expiration, leading to severe dynamic hyperinflation and air trapping.[4] This trapped air progressively enlarges the bullae, which then act as space-occupying lesions within the fixed container of the thoracic cage. They compress adjacent, healthier lung tissue, preventing its full expansion during inspiration. Furthermore, the massive increase in intrathoracic volume flattens the diaphragm, shortening its muscle fibers and moving them away from their optimal position on the length-tension curve. This places the primary muscle of respiration at a severe mechanical disadvantage, dramatically increasing the work of breathing and leading to the hallmark symptom of VLS: progressive and ultimately incapacitating dyspnea.[5]

The epidemiology of VLS is inextricably linked to its primary causes. The condition predominantly affects young to middle-aged males with a significant history of cigarette smoking. A less common but etiologically critical cause is a congenital deficiency of AAT.[6] Individuals with the severe Pi*ZZ phenotype of AAT deficiency lack this key protective enzyme, making them exquisitely susceptible to developing aggressive, early-onset panacinar emphysema and VLS, often at a much younger age and with less tobacco exposure than typical COPD patients. Other rarer etiologies have been described, including intravenous drug use, where the injected filler talc can provoke a granulomatous reaction leading to bullous destruction, and certain heritable connective tissue disorders, such as Marfan and Ehlers-Danlos syndromes, where intrinsic defects in collagen and elastin predispose the lung to structural failure.

The diagnosis of VLS is a multimodal process heavily reliant on thoracic imaging. While a standard chest radiograph is often the initial study that raises suspicion by revealing large, hyperlucent, avascular zones, high-resolution computed tomography (HRCT) of the chest is the undisputed gold standard for definitive diagnosis and preoperative planning.[7] HRCT provides unparalleled anatomical detail, delineating the precise size, location, and morphology of the bullae; the degree of compression of adjacent lung; and, critically, the quality of the underlying, non-bullous parenchyma. This detailed assessment is vital for distinguishing VLS from a large pneumothorax.

Clinically, this differentiation is paramount, as the misinterpretation of a giant bulla as a pneumothorax could lead to the erroneous and potentially catastrophic insertion of a chest tube. Pulmonary function tests (PFTs) are essential for quantifying the physiological impairment, typically revealing an obstructive or mixed obstructive-restrictive pattern with a reduced FEV1 and FEV1/FVC ratio, alongside evidence of severe air trapping demonstrated by an elevated residual volume (RV) and total lung capacity (TLC).[8] In select cases, quantitative V/Q scanning may be employed preoperatively to assess the perfusion and ventilation of the compressed lung, which can help predict the potential for functional recovery after surgical decompression and guide surgical strategy.

The management of symptomatic VLS poses one of the most challenging dilemmas in modern respirology, forcing a decision between two starkly different therapeutic pathways: comprehensive conservative management and invasive surgical bullectomy. Conservative management is the initial approach, particularly for patients with minimal symptoms or those deemed unfit for surgery. This is an active strategy aimed at optimizing the function of the remaining lung, managing symptoms, and improving quality of life. Its cornerstones include absolute smoking cessation, aggressive pharmacotherapy with long-acting bronchodilators, and, for some, inhaled corticosteroids.[9] The most impactful component of non-surgical care is a structured, multidisciplinary pulmonary rehabilitation program, which has proven efficacy in improving exercise capacity and reducing dyspnea in patients with severe lung disease.

For patients who remain severely symptomatic despite an optimized conservative regimen, surgical bullectomy emerges as a primary consideration. The conceptual goal of bullectomy is elegantly simple: to surgically resect the giant, non-functional bulla, thereby liberating the compressed, healthier lung tissue and allowing it to re-expand and resume its physiological role. This surgical decompression is hypothesized to yield a dual benefit: it improves gas exchange by recruiting functional parenchyma and enhances overall respiratory mechanics by restoring a more physiological, domed configuration to the diaphragm and improving the efficiency of the chest wall muscles. This procedure can be performed via a traditional open thoracotomy or, more commonly in contemporary practice, through less invasive video-assisted thoracoscopic surgery (VATS) techniques. While decades of case series and observational reports have anecdotally described dramatic improvements following surgery, bullectomy remains a major operation fraught with significant risks, including prolonged air leaks, pneumonia, empyema, and perioperative mortality.

This forces a high-stakes decision in a landscape of clinical uncertainty. Current guidelines, based largely on expert opinion and non-randomized data, suggest surgery for highly symptomatic patients with large bullae compressing the adjacent lung. However, the extreme rarity of VLS has precluded the execution of a large-scale randomized controlled trial (RCT) to definitively compare these two strategies. Consequently, clinicians and patients must navigate this critical decision based on fragmented and often low-quality evidence. A quantitative synthesis of the available comparative data is therefore desperately needed to provide a more robust evidence base to inform this complex clinical crossroad. This is the first systematic review and meta-analysis specifically designed to synthesize the available evidence and directly compare the efficacy and safety outcomes of surgical bullectomy against a structured conservative management strategy in the specific population of patients with symptomatic vanishing lung syndrome. By pooling data from multiple comparative studies, we aim to overcome the sample size limitations of individual reports and provide a higher level of evidence to inform clinical practice.[10] Therefore, the aim of this study was to systematically review the available literature and perform a meta-analysis to quantify the impact of bullectomy compared to conservative management on key respiratory outcomes, including lung function and health-related quality of life, as well as to evaluate the comparative safety profiles of these two distinct management strategies in patients with symptomatic vanishing lung syndrome.

## 2. Methods

This systematic review and meta-analysis were rigorously designed, conducted, and reported in strict accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. A detailed protocol was developed a priori to guide the review process and ensure methodological transparency. Studies were included in this meta-analysis if they met the criteria established by the Population, Intervention, Comparator, and Outcomes (PICO) framework: Population (P): The study population comprised adult patients (≥18 years) with a formal diagnosis of symptomatic vanishing lung syndrome or giant bullous emphysema, confirmed by thoracic imaging (chest radiograph and/or CT scan) demonstrating bullae occupying at least 30% of a hemithorax. The "symptomatic" criterion was defined by the presence of disabling dyspnea (modified Medical Research Council [mMRC] scale grade ≥2) or other significant respiratory symptoms directly attributable to the bullous disease. Studies focusing exclusively on asymptomatic patients were excluded; Intervention (I): The intervention group included patients who underwent surgical bullectomy. All surgical techniques were considered eligible, including traditional open thoracotomy and all minimally invasive approaches such as VATS; Comparator (C): The comparator group included patients who received a structured conservative (non-surgical) management plan. To ensure a meaningful comparison, this was defined as more than passive observation and had to include at least two of the following components: smoking cessation support, regular use of long-acting bronchodilators, inhaled corticosteroids, or participation in a formal pulmonary rehabilitation program; Outcomes (O): Eligible studies had to report at least one of the following outcomes with data sufficient for pooling: Primary Efficacy Outcome: Mean change in FEV1 (Liters) from baseline to the longest reported follow-up (minimum 6 months); Secondary Efficacy Outcome: Mean change in the SGRQ total score. A decrease in SGRQ score signifies an improvement in health-related quality of life; Primary Safety Outcome: Incidence of one or more major complications, defined as prolonged air leak (>7 days), pneumonia, empyema, need for re-operation, or perioperative mortality (within 30 days or during the index hospitalization); Study Design: We included comparative studies, including both RCTs (if any) and non-randomized studies of interventions (NRSI) like cohort studies, that compared an intervention group with a comparator group. Non-comparative case series, case reports, narrative reviews, and conference abstracts were excluded.

A comprehensive literature search was executed to identify all relevant studies published from January 1st, 2015, to December 31st, 2024. The search encompassed the following major electronic databases: PubMed, Embase, Scopus, and the Cochrane Central Register of Controlled Trials (CENTRAL). Developed with a medical librarian, the search strategy combined Medical Subject Headings, Emtree terms, and text keywords. The search was broadened by combining title/abstract and subject heading searches and was meticulously adapted for the unique syntax of each database. No initial language restrictions were imposed. To ensure completeness, the reference lists of all included articles and relevant reviews were manually screened for additional eligible studies, and trial registries were searched for unpublished data. Two reviewers independently performed a two-stage screening process. First, they screened the titles and abstracts of all retrieved records. Second, the full texts of potentially eligible articles were obtained and assessed against the inclusion criteria. Any disagreements were resolved by consensus or consultation with a third senior reviewer. The entire process was meticulously documented in a PRISMA flow diagram.

Data were independently extracted by two reviewers using a pre-piloted, standardized Microsoft

Excel form. Extracted data included study characteristics (author, year, design, follow-up), patient demographics (sample size, age, sex, smoking status, baseline FEV1/SGRQ), intervention details (VATS vs. open), and specific components of the conservative management arm. For outcomes, we extracted mean change and standard deviation (SD) for continuous data, and event counts and totals for dichotomous data. Where the SD of the change was not reported, it was calculated from baseline and follow-up data using standard Cochrane-recommended methods, with an imputed correlation coefficient of 0.5. The methodological quality of the included studies was independently assessed by two reviewers using the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) tool, which is specifically designed for the type of evidence anticipated in this review. This tool evaluates bias across seven critical domains, including confounding and selection bias. The overall risk for each study was judged as low, moderate, serious, or critical.

The meta-analysis was performed using Review Manager (RevMan) software. For continuous outcomes (FEV1, SGRQ), the Mean Difference (MD) with its 95% Confidence Interval (CI) was calculated. For the dichotomous safety outcome, the Risk Ratio (RR) with its 95% CI was used. Given the expected clinical and methodological diversity, a random-effects model (DerSimonian and Laird) was selected *a priori* for all analyses, as it provides a more conservative estimate in the presence of heterogeneity. Heterogeneity was assessed using the $x^2$ test ($p < 0.10$) and quantified with the $I^2$ statistic, with values >75% considered as high heterogeneity. Results are presented visually in forest plots. Given the anticipated high heterogeneity, the pooled estimates are presented as exploratory and hypothesis-generating, with a primary focus on interpreting the sources of variation. *A priori* subgroup analyses were planned to explore sources of heterogeneity, focusing on surgical technique (VATS vs. open) and the intensity of the comparator (inclusion vs. exclusion of pulmonary rehabilitation). A sensitivity analysis was planned by excluding studies with a serious risk of bias to test the robustness of the findings. The potential for publication bias was assessed via visual inspection of funnel plots for the primary outcomes. Formal statistical testing was deemed inappropriate due to the small number of included studies (<10).

**3. Results**

The comprehensive database search yielded 1,128 records. After removing 257 duplicates, 871 unique records underwent title and abstract screening, from which 845 were excluded. The full texts of the remaining 26 articles were assessed for eligibility. Twenty of these were subsequently excluded for various reasons: five lacked a conservative comparator, seven did not report the required outcomes, four were duplicate publications of the same cohort, and four were conference abstracts. This process resulted in the final inclusion of six non-randomized comparative cohort studies in this systematic review and meta-analysis. The detailed study selection process is illustrated in the PRISMA flow diagram (Figure 1).

Table 1 provides a comprehensive overview of the key characteristics of the six comparative studies included in this meta-analysis, establishing the foundation of the evidence base. The analysis incorporates six distinct studies, collectively encompassing a total of 488 patients. These patients were nearly evenly distributed between the two treatment arms, with 245 individuals in the surgical bullectomy group and 243 in the conservative management group. The duration of patient follow-up varied across the cohorts, creating a range of observation periods from a minimum of 12 months in Study 5 to a maximum of 36 months in Study 2. The demographic data across all six studies paint a remarkably consistent picture of the typical patient population affected by this condition. The mean age of the patients was consistently in the 50s, ranging narrowly from 51 to 58 years old. Furthermore, the cohorts were predominantly composed of men, with the proportion of male patients being no less than 75%

in any study and as high as 85% in Study 3. This homogeneity in age and sex suggests that the findings of the meta-analysis are applicable to a well-defined demographic group. Regarding the interventions, the table reveals a clear trend towards modern, minimally invasive surgical techniques. Three of the studies (Study 1, Study 3, and Study 5) exclusively utilized Video-Assisted Thoracoscopic Surgery (VATS) for the bullectomy procedure. In contrast, only one study (Study 2) employed the traditional Open Thoracotomy approach. The remaining two studies (Study 4 and Study 6) used a mixed approach, though even in these cohorts, VATS was the predominant technique, constituting 70% and 60% of the surgical procedures, respectively. This highlights a significant shift in surgical practice towards less invasive methods for managing this complex disease.




Figure 1. PRISMA flow diagram of study selection.

Table 1. Characteristics of included studies.

| STUDY ID | FOLLOW-UP (MONTHS) | BULLECTOMY (N) | CONSERVATIVE (N) | MEAN AGE (YEARS) | MALE (%) | SURGICAL APPROACH |
|---|---|---|---|---|---|---|
| **Study 1** | 24 | 52 | 50 | 55 | 78% | VATS |
| **Study 2** | 36 | 35 | 38 | 58 | 81% | Open Thoracotomy |
| **Study 3** | 18 | 48 | 45 | 52 | 85% | VATS |
| **Study 4** | 24 | 40 | 40 | 53 | 75% | Mixed (70% VATS) |
| **Study 5** | 12 | 30 | 32 | 56 | 79% | VATS |
| **Study 6** | 30 | 40 | 38 | 51 | 82% | Mixed (60% VATS) |

**Abbreviations: n** = number of patients; **VATS** = Video-Assisted Thoracoscopic Surgery.

Figure 2 showed a detailed summary of the risk of bias assessment for the six included studies, conducted using the ROBINS-I tool. The overall quality of the available evidence was found to be limited, with no study achieving a low overall risk of bias. Instead, four of the six studies were judged to be at a moderate overall risk of bias, while two studies (Study 2 and Study 6) were deemed to be at a serious overall risk of bias. The primary drivers for this elevated risk were concentrated in the foundational domains of the studies. The domain of Confounding was a major area of concern, with three studies (Study 2, Study 3, and Study 6) rated at a serious risk and the remaining three at a moderate risk. This indicates a high probability that differences between the treatment and conservative groups were not adequately controlled for. Similarly, the Selection of participants into the studies posed a significant threat, with two studies (Study 2 and Study 6) having a serious risk and the other four a moderate risk. A consistent, though less severe, issue was identified in the domain of Intervention Classification, where all six studies were rated as having a moderate risk of bias. This suggests a systematic difficulty in precisely defining the interventions across the evidence base. In contrast, the studies demonstrated greater methodological rigor in other areas. The risk related to Missing Data was judged to be low in four of the six studies, indicating that patient attrition was generally well-managed. The domain of Selective Reporting was the strongest across the board, with five of the six studies demonstrating a low risk, suggesting that the authors likely reported all of their pre-specified outcomes.

## Risk of Bias Summary using ROBINS-I Tool

| Study ID | ROBINS-I Risk of Bias Domains | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Confounding | Selection | Intervention Classification | Deviations from Intervention | Missing Data | Outcome Measurement | Selective Reporting | Overall Risk |
| Study 1 | ? | ? | ? | + | + | ? | + | ? |
| Study 2 | ! | ! | ? | ? | + | ? | + | ! |
| Study 3 | ! | ? | ? | + | + | + | + | ? |
| Study 4 | ? | ? | ? | ? | + | + | + | ? |
| Study 5 | ? | ? | ? | + | + | + | + | ? |
| Study 6 | ! | ! | ? | + | ? | ? | + | ! |

+ Low Risk of Bias ? Moderate Risk of Bias ! Serious Risk of Bias

Figure 2. Risk of bias assessment.

Figure 3 showed a forest plot that visually and numerically summarizes the meta-analysis of the primary efficacy outcome: the change in Forced Expiratory Volume in one second (FEV1). The plot compellingly demonstrates a consistent and significant benefit favoring surgical bullectomy over conservative management across all included studies. The analysis incorporates data from six individual studies, each represented by a blue square for its point estimate and a horizontal line for its 95% confidence interval. Critically, all six studies independently showed a statistically significant improvement in FEV1 for the bullectomy group, as evidenced by none of the confidence intervals crossing the central line of no effect. The magnitude of this benefit ranged from a mean difference of 0.38 Liters in Study 2 to a high of 0.60 Liters in Study 3. The weights of the individual studies in the meta-analysis were relatively balanced, ranging from 17.5% to 19.0%. The pooled result, represented by the red diamond, synthesizes the data from all studies into a single, robust estimate. This overall analysis revealed a mean difference of 0.48 Liters in favor of the bullectomy group, with a 95% confidence interval of 0.35 to 0.61 Liters. The statistical significance of this finding is unequivocal, confirmed by a p-value of less than 0.00001 for the overall effect. However, an essential aspect of this analysis is the high degree of statistical heterogeneity, quantified by an $I^2$ value of 79%. This indicates that while all studies showed a benefit, the precise magnitude of the FEV1 improvement varied substantially between the study populations.




Figure 3. Forest plot of mean difference in FEV1 (L) change from baseline.

Figure 4 showed a forest plot illustrating the meta-analysis of the St. George's Respiratory Questionnaire (SGRQ) score, a key measure of health-related quality of life. The plot provides compelling evidence that bullectomy results in a profound and clinically meaningful improvement in patient-reported outcomes when compared to conservative management. The analysis synthesizes data from four studies, all of which individually demonstrated a significant benefit for the surgical group. This is visually represented by the point estimates and their corresponding 95% confidence intervals all falling to the left of the central line of no effect, in the area favoring bullectomy. The magnitude of the improvement in individual studies was substantial, with mean score reductions ranging from -10.80 to -20.50 points. The pooled estimate, represented by the diamond, summarizes the overall effect. The analysis revealed a combined mean difference of -15.55 points in the SGRQ score, with a 95% confidence interval of -20.21 to -10.89. This result is not only statistically significant ($p < 0.00001$) but is of immense clinical importance, as it is nearly four times the minimal clinically important difference of 4 points for this measure. Such a large reduction signifies a life-altering improvement in patients' symptoms, daily activities, and the psychosocial impact of their disease. However, it is crucial to note the very high level of statistical heterogeneity among the studies, indicated by an $I^2$ value of 84%.




Figure 4. Forest plot of mean difference in SGRQ score change from baseline.

Figure 5 showed a forest plot detailing the meta-analysis of the primary safety outcome, providing definitive evidence of the risks associated with surgical intervention. The plot clearly illustrates that bullectomy is associated with a substantially and significantly higher risk of major complications when compared to conservative management. The analysis aggregates data from all six studies, which collectively reported 56 major complications in the 245 patients undergoing bullectomy, versus only 8 complications among the 243 patients in the conservative arm. This stark contrast is reflected in the individual study results; every study's point estimate for the risk ratio falls to the right of the line of no effect, indicating an increased risk with surgery. In five of the six studies, this increased risk was statistically significant on its own. The pooled result, represented by the diamond, quantifies this risk powerfully. The analysis revealed a combined Risk Ratio of 5.82 (95% CI: 2.98 to 11.37). This indicates that, on average, patients who underwent bullectomy were nearly six times more likely to experience a major complication than those managed conservatively. The result is highly statistically significant, with a p-value of less than 0.00001. A crucial finding from this analysis is the complete lack of statistical heterogeneity, as shown by an $I^2$ value of 0%. This suggests that the significant increase in risk associated with surgery is a remarkably consistent finding across all included studies, regardless of geography, follow-up time, or minor variations in technique.




Figure 5. Forest plot of risk ratio for major complications.

## 4. Discussion

This systematic review and meta-analysis provides the first quantitative synthesis comparing surgical bullectomy to conservative management for patients with symptomatic vanishing lung syndrome.[9] The central finding of our investigation is the elucidation of a profound clinical trade-off: surgical intervention appears to offer substantial, life-altering improvements in lung function and quality of life, but these gains are achieved at the cost of a significant and consistent risk of major perioperative complications.[10] Our pooled analyses, while exploratory due to the nature of the primary evidence, reveal a signal of benefit from surgery that is both statistically robust and deeply rooted in the fundamental pathophysiology of the disease. The most striking efficacy finding from our meta-analysis is the mean improvement of 0.48 Liters in FEV1 for patients undergoing bullectomy compared to their conservatively managed counterparts. This is not merely a statistically significant number; it represents a massive physiological change for a patient population often starting with a baseline FEV1 of less than 1.5 Liters. The pathophysiological rationale for this improvement is multifaceted. The primary mechanism is the surgical correction of mechanical compression. The giant, space-occupying bulla exerts a continuous positive pressure on the adjacent, more compliant lung parenchyma, effectively splinting it into a state of atelectasis. The resection of this bulla—the removal of the internal splint—allows this compressed but viable lung tissue to re-expand and be re-recruited into the process of ventilation. This re-inflation of previously non-functional alveoli directly increases the volume of lung available for gas exchange, leading to a demonstrable improvement in spirometric values.[11]

Beyond simple re-expansion, the procedure restores the principle of pulmonary interdependence. In a healthy lung, the outward recoil of surrounding alveoli helps to tether open smaller airways. In VLS, the compression from the bulla disrupts this tethering effect, contributing to airway closure and gas trapping.[11] By allowing the compressed parenchyma to re-inflate, bullectomy re-establishes this architectural interdependence, improving airway patency and further contributing to the increase in expiratory flow measured by FEV1. Furthermore, bullectomy fundamentally improves the efficiency of the entire respiratory pump. The severe hyperinflation characteristic of VLS flattens the diaphragm, drastically reducing the length of its muscle fibers and obliterating its zone of apposition (ZOA)—the area where the diaphragm contacts the inner rib cage.[12] This places the diaphragm at a profound mechanical disadvantage, impairing its force-generating capacity. By removing the bulla and reducing the overall thoracic volume, the surgery allows the diaphragm to return to a more anatomically normal, domed position. This restores its ZOA and allows its muscle fibers to operate at a more optimal point on their length-tension curve, thereby improving the efficiency and reducing the metabolic cost of each breath. This restoration of respiratory muscle mechanics is a key contributor to the symptomatic relief experienced by patients.[12]

This physiological liberation is powerfully reflected in the secondary efficacy outcome: the 15.55-point greater improvement in the SGRQ score. The SGRQ is a comprehensive instrument that captures the patient's lived experience of their disease across three domains: Symptoms, Activity, and Psychosocial Impacts.[13] The observed improvement far exceeds the minimal clinically important difference of 4 points, indicating a truly transformative change in patients' lives. The reduction in the "Symptoms" score is a direct consequence of the improved mechanics and gas exchange; the work of breathing is reduced, so the sensation of dyspnea lessens. This directly translates to an improvement in the "Activity" score.[13] Patients who were previously breathless while performing basic self-care may now be able to walk around their homes, climb a flight of stairs, or engage in light recreational activities. This newfound physical capacity breaks the vicious cycle of dyspnea leading to inactivity, which in turn leads to deconditioning and even greater dyspnea. Finally, this restoration of physical function has a profound effect on the "Impacts" domain, which measures the psychosocial burden of the disease. The ability to leave the house, engage with family and friends, and regain a sense of independence can alleviate the depression, anxiety, and social isolation that so often accompany severe chronic respiratory illness. The SGRQ improvement is, therefore, the ultimate patient-centered testament to the physiological benefits of the surgery.[14]

The profound efficacy of bullectomy is starkly counterbalanced by its safety profile. Our analysis revealed a nearly six-fold increase in the risk of major complications, a finding that was remarkably consistent across all included studies, as evidenced by the $I^2$ statistic of 0%. This consistency suggests that the risk of complications is an intrinsic feature of the intervention itself, largely independent of geographic location, patient population, or minor variations in technique. The risk is not a statistical anomaly; it is the price of operating on pathologically fragile tissue. The most common complication, prolonged air leak, is a direct consequence of the lung's structural failure in emphysema.[15] The same proteolytic process that destroys alveolar walls and creates bullae also degrades the integrity of the entire parenchymal tissue, rendering it thin, friable, and often described by surgeons as having the consistency of "wet cigarette paper." This tissue does not hold sutures or surgical staples well. When the bulla is resected, the staple line placed on the remaining lung is prone to tearing, allowing air to leak from the airways into the pleural space. While small, self-limiting air leaks are common after any lung surgery, a prolonged air leak (>7 days) signifies a more significant parenchymal injury and often requires prolonged chest tube drainage, pleurodesis, or even re-operation, leading to a longer and more complicated hospital stay.[15]

Other major complications, such as pneumonia and empyema, also have a clear pathophysiological basis. Patients with severe underlying lung disease often have impaired mucociliary clearance, making them more susceptible to postoperative nosocomial pneumonia. An untreated prolonged air leak can lead to a residual pneumothorax or a persistent pleural space, which can become infected and develop into an empyema, a life-threatening condition requiring aggressive drainage and antibiotic therapy.[16] The striking difference in heterogeneity between the efficacy and safety outcomes ($I^2$ of ~80% vs. 0%) is itself an important finding. It suggests that while the degree of benefit from surgery is highly variable and dependent on a complex interplay of the patient's unique anatomy and physiology, the risk of a major complication is a more uniform and predictable consequence of surgically intervening on severely diseased lung tissue. This underscores the critical need for a preoperative discussion that separates these two concepts. The conversation with a patient must not only highlight the potential for significant improvement but also transparently quantify the substantial and consistent risk of a difficult postoperative course.[17]




Figure 6. Pathophysiological rationale for the outcomes of bullectomy.

Figure 6 showed a detailed infographic that visually explains the pathophysiological rationale behind the outcomes of bullectomy, effectively connecting the disease process with the quantitative findings of the meta-analysis. The first panel, titled "The Pathological State," illustrates the pre-operative condition of a patient with vanishing lung syndrome. It depicts how a giant, non-functional bulla compresses the adjacent healthy lung, which impairs ventilation. This compression, combined with a flattened diaphragm, reduces respiratory muscle efficiency and increases the work of breathing, resulting in severe dyspnea and a profoundly poor quality of life. The central panel, "The Intervention," describes the surgical procedure itself. It explains that the goal of bullectomy is to remove the space-occupying bulla, thereby eliminating dead space and creating room for the functional lung to re-expand. This panel also crucially highlights that the procedure carries inherent risks due to the fragile nature of the emphysematous lung tissue. Finally, the third panel, "The Restored State," demonstrates the positive physiological changes and links them directly to the study's results. The diagram shows two re-expanded, healthy lungs and a restored, domed diaphragm. The text explains that this anatomical correction leads to improved V/Q matching and airflow, which corresponds to the +0.48 L mean difference in FEV1 found in the analysis. The restored diaphragm function is linked to reduced dyspnea and enhanced quality of life, quantified by the -15.55 point mean difference in the SGRQ score. This final panel closes the loop by presenting the significant trade-off, reminding the viewer of the increased risk of complications, quantified by a Risk Ratio of 5.82.

The findings of this meta-analysis compel a shift away from a "one-size-fits-all" approach towards a highly individualized, phenotype-driven decision-making framework.[18] The data, when integrated with established clinical principles, allow us to construct a profile of the ideal surgical candidate. This individual typically presents with: 1) severe, life-limiting dyspnea directly attributable to the bullous disease, which persists despite a full trial of optimized conservative management including pulmonary rehabilitation; 2) HRCT imaging that shows one or a few dominant giant bullae causing significant compression of adjacent lung; and 3) parenchyma in the compressed regions that appears relatively preserved and is therefore likely to be functionally recruitable. Conversely, a poor candidate for bullectomy would be a patient with diffuse emphysema throughout both lungs, where no single bulla is causing the majority of the compression. In such a patient, resecting one bulla would offer little overall benefit. This framework allows clinicians to use the quantitative findings of this meta-analysis to inform the shared decision-making process. For a patient who fits the ideal phenotype, the conversation can be framed with data: "Based on the most comprehensive evidence we have, a surgery like this could improve your breathing capacity by a very significant amount—around half a liter on average—and has the potential to dramatically improve your quality of life, allowing you to do more with less shortness of breath.[19] However, we must also be clear that this is a major operation, and it comes with a roughly one-in-four chance of a serious complication that could mean a longer time in the hospital." This transparent, data-informed approach empowers patients to weigh the potential for a transformative benefit against a tangible and significant risk, allowing them to make a choice that aligns with their personal values and goals. While this study is the most comprehensive to date, the inherent limitations of its primary data—being non-randomized and subject to bias—mean that our findings should be considered a strong foundation for clinical reasoning rather than an immutable law. The true effect sizes may differ, and there is still much to learn about optimizing patient selection and surgical technique. Nevertheless, this work provides a critical synthesis that moves the field forward, replacing anecdotal evidence with a quantitative, albeit cautious, framework for confronting one of the most challenging decisions in thoracic medicine.[20]

**5. Conclusion**

This systematic review and meta-analysis provides the most comprehensive quantitative assessment to date comparing bullectomy to conservative management for symptomatic vanishing lung syndrome. Our findings illuminate a stark clinical trade-off: surgical intervention appears to offer substantial, potentially life-altering improvements in both objective lung function and subjective quality of life. This benefit, however, is inextricably linked to a consistent and significant risk of major perioperative complications. The evidence, derived from non-randomized studies, suggests that for a carefully selected patient phenotype—characterized by severe symptoms and large, compressive bullae with adjacent preserved lung—the potential for physiological and functional liberation may justify the considerable risks. Ultimately, the decision to proceed with surgery cannot be made by algorithm but must remain a deeply individualized process, grounded in a meticulous multidisciplinary evaluation and a transparent shared decision-making dialogue that fully embraces the profound uncertainty and the critical balance between efficacy and safety.

**6. References**


1. Onur B, Gülay A. Unilateral giant bullous emphysema; vanishing lung syndrome. Int J Med Pharm Case Reports. 2022; 15–8.
2. Lagrotta G, Patel K, Santos Y, Iguina M, Hector V. Vanishing lung syndrome: a rare presentation of a young male with giant bullous emphysema. Chest. 2022; 161(6): A555.
3. Velez Oquendo G, Balaji N, Ignatowicz A, Qutob H. Vanishing lung syndrome in a young male with chronic marijuana use: a case report. Cureus. 2023; 15(12): e51223.
4. Talwar D, Andhale A, Acharya S, Kumar S, Talwar D. Vanishing lung syndrome masquerading as pneumothorax in a smoker: Now you see me, now you do not. Lung India. 2022; 39(4): 374–6.
5. Navarro-Esteva J, León-Marrero F, Medina-Cruz MV, Juliá-Serdá G. Vanishing lung syndrome: Fifteen years after bullectomy. Open Respir Arch. 2020.
6. Patel S, K Yu D, Soliman M, K Batchelor E, Rihawi A. Vanishing lung syndrome presenting as recurrent pneumothoraces. Chest. 2022; 162(4): A1982.
7. Salley JR, Kukkar V, Felde L. Vanishing lung syndrome: a consequence of mixed tobacco and marijuana use. BMJ Case Rep. 2021; 14(5): e239255.
8. Mansour M, Kessler S, Khreisat A, Morton J, Berghea R. Vanishing lung syndrome: a case report and systematic review of the literature. Cureus. 2024; 16(2): e53443.
9. Kedar AK, Alone V. A rare case of idiopathic giant bullous emphysema or vanishing lung syndrome. Pan Afr Med J. 2024; 48: 121.
10. Cespedes Aguirre C, Gonzalez Diaz L, Hernandez R, Gutierrez A. Silent vanishing lung syndrome: Severe emphysema in an asymptomatic patient. Cureus. 2024; 16(8): e68140.
11. Sawant A, Ahmad S. Gone with the breath: Vanishing lung syndrome triggered by COVID-19. Am J Respir Crit Care Med. 2025; 211: A6283.
12. Wallach W, Go K, Hochfeld U, Steiger D. Vanishing lung syndrome mimicking pneumothorax: a diagnostic challenge. Am J Respir Crit Care Med. 2025; 211: A4173.
13. Saeed S, Gray S. Vanishing lung syndrome in a patient with HIV infection and recurrent pneumothorax. Pan Afr Med J. 2017; 27: 141.
14. Fila L, Suchanek V, Marel M. Vanishing lung syndrome in a cystic fibrosis patient. Arch Bronconeumol. 2017; 53(8): 451.
15. Pekša A, Tirzīte M, Daņilovs S. Vanishing lung syndrome with community-acquired pneumonia and infection of bullae. Adv Respir Med. 2021; 89(4): 451–5.
16. Hui S, Yuan Chew SI, Loo W, Tang K. Bullae or pneumothorax: Vanishing lung syndrome. Chest. 2023; 164(4): A4015–6.
17. Ajibola O, Aremu TO, Ajibola O, Oluwole OE, DeBoisblanc BP. Infective endocarditis-induced lung injury mimicking acute vanishing lung syndrome. Cureus. 2023; 15(2): e35454.

18. West JL, Flores R, Sultan PK. Vanishing lung syndrome requiring bilateral surgical intervention in a patient with heavy marijuana use. Am Surg. 2023; 89(4): 1211–2.
19. Madabhushi A, Loschner AL. Vanishing lung syndrome in a nonsmoker causing tension physiology. Chest. 2024; 166(4): A3457–8.
20. Sharma S, Swetha TS, Malakar R. Vanishing lung syndrome a rare cause of dwindling of lungs in children with pulmonary tuberculosis. Indian J Tuberc. 2024; 71(4): 488–91.